VEGF News and Research

RSS

VEGF is a substance made by cells that stimulates new blood vessel formation. Also called vascular endothelial growth factor.

Bevacizumab offers no benefit for patients newly diagnosed with glioblastoma

Adding bevacizumab (Avastin) to standard chemotherapy and radiation treatment does not improve survival for patients newly diagnosed with the often deadly brain cancer glioblastoma, researchers report in the Feb. 20 issue of the New England Journal of Medicine.

20 Feb 2014

Bayer enrolls patients for Phase III trial of Stivarga (regorafenib) tablets in colorectal cancer

Bayer HealthCare today announced that the company has begun to enroll patients in the COAST trial studying Stivarga® (regorafenib) tablets in colorectal cancer (CRC) patients with resected liver metastases.

20 Feb 2014

CardioCell announces new clinical trials using allogeneic stem-cell therapy to treat subjects with AMI

CardioCell LLC announces two new clinical trials using its allogeneic stem-cell therapy to treat subjects with acute myocardial infarction (AMI), a problem facing more than 1.26 million Americans annually.

20 Feb 2014

Aerpio Therapeutics doses first patient in AKB-9778 Phase 2 trial for diabetic macular edema treatment

Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases, today announced that it has dosed the first patient in a Phase 2 trial evaluating AKB-9778, a Tie2 activator, alone and in combination with ranibizumab (Lucentis) for the treatment of diabetic macular edema (DME). AKB-9778 is a first-in-class inhibitor of human protein tyrosine phosphatase beta (HPTPβ) that activates the Tie2 pathway to promote vascular stability, preventing abnormal blood vessel growth and vascular leak.

13 Feb 2014

Researchers discover highly accurate, noninvasive test to identify benign pancreatic cysts

Researchers at the Indiana University School of Medicine have discovered a highly accurate, noninvasive test to identify benign pancreatic cysts, which could spare patients years of nerve-racking trips to the doctor or potentially dangerous surgery.

12 Feb 2014

Study: Ipilimumab with VEGF inhibitors may be potential option for melanoma patients

Among patients with advanced melanoma, presence of higher levels of the protein vascular endothelial growth factor (VEGF) in blood was associated with poor response to treatment with the immunotherapy ipilimumab, according to a study published in Cancer Immunology Research, a journal of the American Association for Cancer Research.

5 Feb 2014

Pfizer and Merck join forces to explore therapeutic potential of anti-PD-1 therapy

Pfizer Inc. announced today that it has agreed with Merck & Co., Inc., known as MSD outside the United States and Canada ("Merck"), through two Merck subsidiaries, to explore the therapeutic potential of Merck's investigational anti-PD-1 therapy, MK-3475, in combination with two Pfizer oncology assets.

5 Feb 2014

FDA approves Ocular Therapeutix’s ReSure Sealant for ophthalmic use

Ocular Therapeutix announced today it has received approval from the Food and Drug Administration to commercialize the ReSure Sealant in the United States, with an indication for prevention of postoperative fluid egress from incisions with a demonstrated wound leak following cataract surgery.

10 Jan 2014

Synta initiates three multicenter trials to evaluate ganetespib with chemotherapy for AML and MDS

Synta Pharmaceuticals Corp. today announced the initiation of three multicenter, randomized trials supported by the Leukemia & Lymphoma Research Fund and Cancer Research UK, evaluating ganetespib in combination with chemotherapy in first-line treatment of patients with AML and high risk MDS.

10 Jan 2014

Study shows beneficial effects of normobaric oxygen on cerebral ischemic injury

Normobaric oxygen has the rapid and non-invasive characteristics and may have therapeutic effects on ischemic/hypoxic disease.

28 Dec 2013

Hypoxic preconditioning has protective effects against acute cerebral infarction

Hypoxic preconditioning has been shown to have protective effects against acute cerebral infarction. To investigate the protective mechanisms of hypoxic preconditioning in relation to its effects on angiogenesis, Prof. Xunming Ji and team from Xuanwu Hospital, Capital Medical University in China induced a photochemical model of cerebral infarction in an inbred line of mice (BALB/c) which were exposed to hypoxic preconditioning prior to model establishment.

24 Dec 2013

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted for standard review the Company's supplemental Biologics License Application for EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema.

18 Dec 2013

Combination of ramucirumab and docetaxel fails to delay advanced breast cancer progression

Adding the antibody therapy ramucirumab to the chemotherapy drug docetaxel did not delay disease progression for patients with HER2-negative, advanced breast cancer, according to results of a placebo-controlled, randomized, phase III clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

16 Dec 2013

New drug combination therapy effective for patients with HER2-positive breast cancer

Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer, regardless of tumor size and whether or not disease has spread to the lymph nodes, according to results from the BETH study presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

11 Dec 2013

Low sodium levels linked to poor targeted therapy outcomes in RCC

Low serum sodium levels in patients receiving targeted therapy for metastatic renal cell carcinoma (mRCC) may signal a poor outcome, study findings indicate.

11 Dec 2013

Early tumor shrinkage predicts targeted therapy efficacy in RCC

Early tumor shrinkage in patients with metastatic renal cell carcinoma following vascular endothelial growth factor-targeted therapy may herald good long-term survival, research shows.

11 Dec 2013

Certain hormones which are increased during exercise may help improve memory

Researchers at Boston University School of Medicine (BUSM) have found further evidence that exercise may be beneficial for brain health and cognition. The findings, which are currently available online in Behavioural Brain Research, suggest that certain hormones, which are increased during exercise, may help improve memory.

3 Dec 2013

Study reveals new mechanism that may block formation of new blood vessels and cancer growth

A study led by researchers at Boston University School of Medicine demonstrates a new mechanism involving a signaling protein and its receptor that may block the formation of new blood vessels and cancer growth. The findings are published in the December issue of Science Signaling.

29 Nov 2013

EYLEA Injection gets approval in Japan for treatment of macular edema following CRVO

Regeneron Pharmaceuticals, Inc. today announced that EYLEA (aflibercept) Injection has received approval for the treatment of Macular Edema Following Central Retinal Vein Occlusion from the Japanese Ministry of Health, Labour and Welfare.

22 Nov 2013

Attractants prevent maturing nerve cells from migrating into brain

A vision is to implant nerve precursor cells in the diseased brains of patients with Parkinson's and Huntington's diseases, whereby these cells are to assume the function of the cells that have died off.

21 Nov 2013

VEGF News and Research

Further Reading

Bevacizumab offers no benefit for patients newly diagnosed with glioblastoma

Bayer enrolls patients for Phase III trial of Stivarga (regorafenib) tablets in colorectal cancer

CardioCell announces new clinical trials using allogeneic stem-cell therapy to treat subjects with AMI

Aerpio Therapeutics doses first patient in AKB-9778 Phase 2 trial for diabetic macular edema treatment

Researchers discover highly accurate, noninvasive test to identify benign pancreatic cysts

Study: Ipilimumab with VEGF inhibitors may be potential option for melanoma patients

Pfizer and Merck join forces to explore therapeutic potential of anti-PD-1 therapy

FDA approves Ocular Therapeutix’s ReSure Sealant for ophthalmic use

Synta initiates three multicenter trials to evaluate ganetespib with chemotherapy for AML and MDS

Study shows beneficial effects of normobaric oxygen on cerebral ischemic injury

Hypoxic preconditioning has protective effects against acute cerebral infarction

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

Combination of ramucirumab and docetaxel fails to delay advanced breast cancer progression

New drug combination therapy effective for patients with HER2-positive breast cancer

Low sodium levels linked to poor targeted therapy outcomes in RCC

Early tumor shrinkage predicts targeted therapy efficacy in RCC

Certain hormones which are increased during exercise may help improve memory

Study reveals new mechanism that may block formation of new blood vessels and cancer growth

EYLEA Injection gets approval in Japan for treatment of macular edema following CRVO

Attractants prevent maturing nerve cells from migrating into brain

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo